Basel Medical Group Ltd
BMGL
$4.18
$0.01140.27%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.83M | 1.85M | 1.89M | 1.89M | 1.74M |
| Total Other Revenue | 6.60K | 6.70K | 600.00 | 600.00 | 16.00K |
| Total Revenue | 1.84M | 1.86M | 1.89M | 1.89M | 1.76M |
| Cost of Revenue | 1.22M | 1.23M | 961.10K | 961.10K | 788.30K |
| Gross Profit | 623.10K | 629.20K | 925.30K | 925.30K | 968.80K |
| SG&A Expenses | 258.00K | 260.50K | 1.20K | 1.20K | 386.70K |
| Depreciation & Amortization | 97.40K | 98.30K | 98.30K | 98.30K | 88.10K |
| Other Operating Expenses | 169.90K | 171.50K | 131.20K | 131.20K | 7.40K |
| Total Operating Expenses | 1.74M | 1.76M | 1.19M | 1.19M | 1.27M |
| Operating Income | 97.90K | 98.80K | 694.70K | 694.70K | 486.50K |
| Income Before Tax | 172.30K | 174.00K | 718.20K | 718.20K | 572.50K |
| Income Tax Expenses | -103.30K | -104.30K | 226.60K | 226.60K | 132.10K |
| Earnings from Continuing Operations | 275.70K | 278.40K | 491.60K | 491.60K | 440.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 275.70K | 278.40K | 491.60K | 491.60K | 440.40K |
| EBIT | 97.90K | 98.80K | 694.70K | 694.70K | 486.50K |
| EBITDA | 103.10K | 104.20K | 700.50K | 700.50K | 492.10K |
| EPS Basic | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.03 | 0.03 | 0.02 |
| EPS Diluted | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.03 | 0.03 | 0.02 |
| Average Basic Shares Outstanding | 16.25M | 16.25M | 16.25M | 16.25M | 16.25M |
| Average Diluted Shares Outstanding | 16.25M | 16.25M | 16.25M | 16.25M | 16.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |